4.5
Enfermedad pulmonar obstructiva crónica I: Introducción
La enfermedad pulmonar obstructiva crónica es un trastorno respiratorio común, prevenible y tratable, caracterizado por síntomas persistentes y una li…
La enfermedad pulmonar obstructiva crónica, o EPOC, es un trastorno pulmonar común, prevenible y tratable. Presenta síntomas respiratorios persistentes y limitaciones en el flujo de aire, generalmente causadas por la exposición prolongada a partículas o gases nocivos que provocan inflamación crónica y daño pulmonar.
En la EPOC, la inflamación crónica provoca cambios duraderos en las vías respiratorias y los sacos respiratorios. Estos cambios pueden incluir enfisema, que afecta a los sacos respiratorios, y, en algunas personas, signos de bronquitis crónica, como tos y exceso de moco.
Los principales factores de riesgo incluyen el humo del tabaco, la exposición ocupacional al polvo y a los vapores químicos, y la contaminación del aire interior por el uso de combustible de biomasa para cocinar y calentar en viviendas mal ventiladas.
Otros riesgos incluyen infecciones como la tuberculosis o infecciones respiratorias infantiles repetidas como la neumonía.
Un factor genético clave es la deficiencia de alfa-1 antitripsina, una condición que afecta la capacidad pulmonar para contrarrestar enzimas proteolíticas, lo que conduce a un daño tisular acelerado y a un mayor riesgo de EPOC de inicio precoz.
View the full transcript and gain access to JoVE Core videos
Q1: What causes chronic obstructive pulmonary disease?
COPD results from long-term exposure to harmful particles or gases causing chronic inflammation and lung damage. Major risk factors include tobacco smoke, occupational dust and chemical fumes, indoor air pollution from biomass fuels, and infections like tuberculosis or repeated childhood pneumonia. Genetic factors, particularly alpha-1 antitrypsin deficiency, also increase susceptibility to early-onset COPD.
Q2: How does chronic inflammation damage the lungs in COPD?
Chronic inflammation causes lasting structural changes in airways and air sacs. These changes include emphysema, which destroys alveolar walls and reduces elastic recoil, and chronic bronchitis, characterized by airway inflammation and excess mucus production. Together, these pathological processes limit airflow and impair gas exchange.
Q3: What is the difference between emphysema and chronic bronchitis in COPD?
Emphysema involves destruction of alveolar walls and loss of elastic recoil in air sacs. Chronic bronchitis is defined by chronic cough and sputum production due to airway inflammation and mucus hypersecretion. Although distinct in origin, these conditions often coexist in COPD patients and together contribute to airflow limitation.
Q4: Why is alpha-1 antitrypsin deficiency a genetic risk factor for COPD?
Alpha-1 antitrypsin is a protective enzyme that counteracts proteolytic enzymes in the lungs. Deficiency of this protein impairs the lungs' ability to defend against tissue-damaging enzymes, leading to accelerated lung damage and increased risk of early-onset emphysema even with minimal environmental exposure.
Q5: How do occupational and environmental exposures contribute to COPD development?
Long-term occupational exposure to dust such as silica and cotton, and chemical fumes, damages lung tissue over time. Indoor air pollution from biomass fuels in poorly ventilated homes and urban air pollution also increase COPD risk. These exposures accumulate gradually, leading to progressive lung damage and airflow limitation.
Q6: What role do early-life factors play in COPD susceptibility?
Early-life factors including recurrent respiratory infections, poor lung development from prematurity, and childhood asthma increase susceptibility to COPD later in life. These conditions may compromise initial lung development and function, making individuals more vulnerable to subsequent environmental exposures and chronic inflammation.
Q7: Is COPD preventable and treatable?
Yes, COPD is preventable and treatable. It is a common lung disorder characterized by persistent respiratory symptoms and airflow limitation. Prevention focuses on avoiding harmful exposures like tobacco smoke and occupational hazards, while treatment aims to manage symptoms and slow disease progression.